Compare SNAL & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNAL | BOLD |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.1M | 36.5M |
| IPO Year | 2022 | 2024 |
| Metric | SNAL | BOLD |
|---|---|---|
| Price | $0.81 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 10.8M | 129.5K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $81,225,622.00 | N/A |
| Revenue This Year | $15.53 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.34 | $0.96 |
| 52 Week High | $2.16 | $1.68 |
| Indicator | SNAL | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 53.01 |
| Support Level | $0.62 | $1.40 |
| Resistance Level | $0.98 | $1.53 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 7.40 | 51.43 |
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.